KEM
Kemikalieinspektionen
Swedish Chemicals Agency

Date: 2023-06-10

Development of Legislation and Other Instruments

BPC-51: SE minority opinion on dinotefuran, product-type 18

Sweden proposes to include a condition in the decision on renewal of approval of the active substance on restricting the placing on the market of articles treated with or incorporating dinotefuran, because use in treated articles had not been assessed.

Sweden requests that the provisions of the BPR should be applied as intended. The provisions of Article 58(2) - dealing with placing on the market of treated articles - state that the active substance shall be approved for the relevant product type **and use**. In order to decide whether a use in treated articles can be approved, it is required that the assessment of the use in treated articles must be carried out at the level of active substance evaluation.

Failure to specify the assessed and approved use at substance approval will allow the placing of treated articles on the market without a risk and efficacy assessment of this use - as required by the BPR - and without the possibility to set conditions or prescribe measures necessary to mitigate possible risks of this use.

Based on the above justifications, Sweden considers it appropriate that dinotefuran shall not be approved for use to treat articles, unless such use has been assessed within the context of the active substance evaluation and found acceptable.

Since the majority of the committee members decided to not support the proposal, Sweden submits this minority opinion.